17 November 2017
DETAILS
The consideration for Amyris Brasil Ltda
(which owns and operates the Brotas 1 production facility)
and intellectual property related to farnesene
(a bio-based key intermediate for many applications)
is US$ 58 million plus an additional value share arrangement
over a three-year period amounting to US$ 37.5 million
(aggregate upfront consideration of US$ 96 million).
In addition to the consideration upfront, there is potential
for a future value share in line with Amyris’ business model.
DSM will continue existing supply-agreements
to Amyris and other parties.
DSM will also supply Amyris with specialty compounds
until it realizes its Brotas 2 specialties production facility.
Amyris is accelerating the construction of its second facility
dedicated to specialty products while maintaining
the manufacturing process development
and business support capability located in Campinas, Brazil.
Subject to customary conditions,
the transaction is expected to close in the next few months.
With the acquisition of the Brotas 1 facility, DSM
adds a state-of-the-art biotechnology-based production site
in Brazil to its global network, with abundant availability
of sustainable raw materials (sugar cane), securing
production capacity for its rich pipeline of sustainable
and bio-based solutions.
Having broad experience in operating large-scale fermentation plants,
DSM will optimize the operational performance of the site.
The strategic alliance between DSM and Amyris started
in May 2017 with an equity investment by DSM in Amyris,
and has since been expanded
with several significant product development collaborations.
The sale of the Brotas 1 facility, which was designed
to produce high volumes of farnesene,
together with the creation of a long-term production relationship
for high-volume farnesene-based intermediates
will enable Amyris to focus on its core strength
of developing breakthrough bioscience technologies
through a portfolio approach that continues
to target key markets,
as well as the production of specialty products.
Chris Goppelsroeder,
President & CEO of DSM Nutritional Products
“Following our equity investment in Amyris and
subsequent product development cooperations,
I am pleased that we can add
a state-of-the-art fermentation-based production facility
to our network.
Our know-how in fermentation, downstream process development
and large-scale manufacturing will allow us to further
improve the operational performance of the facility
while further strengthening our strategic alliance with Amyris”.
Contact
For more Information:
Global Director External Communications
Herman Betten
+31 45 578 2017
media.contacts@dsm.com >
Vice-President Investor Relations
Dave Huizing
+31 45 578 2864
investor.relations@dsm.com >
Amyris, Inc.
Peter DeNardo
+1 (510) 740 7481
investor@amyris.com >
WWW.CHEMWINFO.COM BY KHUN PHICHAI